Fischer Medical Ventures Limited announced on July 30, 2026, that its associate company, Nanomedic Technologies Ltd., has secured import approval from the Central Drugs Standard Control Organisation (CDSCO) for the Spincare Portable Wound Care System. The regulatory clearance, issued under Form MD-27 of the Medical Devices Rules, 2017, permits the import and distribution of the Class C medical device in India. This approval marks a significant milestone as it represents India's first regulatory clearance for a portable electrospun wound care system, positioning the company to capture market share in the advanced wound care sector.

The Spincare system is a handheld device that applies a breathable, transparent nano-fiber film directly onto wounds at the point of care, eliminating the need for traditional dressings in many clinical scenarios. The device is indicated for use across various skin breaches, including partial and full thickness wounds, burns, donor site wounds, surgical incisions, and chronic ulcers. Designed for use by healthcare professionals in clinical environments, the system carries a five-year shelf life. Nanomedic Technologies Ltd., headquartered in Lod, Israel, manufactures the system using proprietary electrospinning technology to create a nano-fiber protective layer that accelerates healing and reduces infection risk.

Fischer Medical Ventures holds exclusive rights to distribute the Spincare system across India and Southeast Asia. The Indian wound care market is valued at approximately USD 380 million in 2026 and is projected to reach USD 1.8 billion by 2033, growing at a compound annual growth rate (CAGR) of approximately 6.4%, according to IMARC Group. Key demand drivers include rising diabetes prevalence, increasing surgical volumes, and the growth of home healthcare. In Southeast Asia, the advanced wound care segment is projected to reach USD 354 million by 2030, with a CAGR of approximately 6.1%, driven by increasing awareness of wound management and a rising burden of chronic diseases in countries such as Indonesia, Malaysia, and Singapore.

Market Opportunity and Regional Growth

The following table outlines the projected market values for the regions where Fischer Medical Ventures holds exclusive distribution rights:

Ravindran Govindan, Chairman and Managing Director of Fischer Medical Ventures Limited, stated that receiving CDSCO clearance is a transformative moment for the company. He noted that the approval opens the door to deploying differentiated wound care technology across Indian hospitals and burn centers, highlighting substantial whitespace in the market.

Regulatory Status and Future Approvals

While the CDSCO approval enables immediate commercialization in India, Nanomedic Technologies Ltd. has submitted an application for U.S. Food and Drug Administration (FDA) approval for the Spincare system. The approval process is currently underway, with the company expecting FDA clearance soon. This potential milestone would further validate the product's safety and efficacy standards and strengthen the group's standing in global markets. The Spincare system has already received regulatory approvals in multiple jurisdictions globally.

What the Numbers Show

The strategic value of this approval lies in the convergence of exclusive distribution rights and high-growth market projections. With the Indian market expected to nearly quintuple from USD 380 million to USD 1.8 billion over seven years, Fischer Medical Ventures is entering the sector at the beginning of a significant expansion cycle. The exclusive nature of the partnership in both India and Southeast Asia provides a protected revenue stream in two of the fastest-growing healthcare markets, mitigating competitive risk during the initial commercialization phase.

Fischer Medical Ventures Limited reported a consolidated net profit of ₹3,101.94 lakh for the financial year ended March 31, 2026, a significant increase from ₹120.79 lakh in the previous year. The company's consolidated revenue from operations for FY26 stood at ₹30,857.56 lakh, compared to ₹11,069.87 lakh in FY25. The Board of Directors has recommended a final dividend of ₹0.05 per equity share for FY26, subject to shareholder approval at the ensuing Annual General Meeting.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹711.94 lakh, contrasting with a profit of ₹131.22 lakh in the same quarter last year. Revenue from operations for Q4FY26 was ₹9,773.04 lakh. On a standalone basis, the company reported a net loss of ₹1,042.29 lakh for FY26 and a loss of ₹898.19 lakh for Q4FY26. Statutory auditors M/s. Bilimoria Mehta & Co., Chartered Accountants, issued an audit report with an unmodified opinion.

Key Metrics

The following table summarizes the audited financial results for the year ended March 31, 2026:

Corporate Actions

The Board approved the appointment of S. Ramanand Aiyer & Co., Chartered Accountants, as internal auditors for the financial year 2026-27. During the quarter, the company transferred its investment in Pellucidcare Health Innovations Pte Ltd to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited, making it a step-down subsidiary. The trading window for designated persons will remain closed until 48 hours after the declaration of financial results.